Key result
UK target-trial emulation protocol evaluates 12-month bleeding risks with DAPT and triple therapy post-ACS.
Why the study?
Real-world bleeding in patients exposed to different regimens of DAPT and triple therapy has a clinical and economic impact but has not been previously quantified.
What is the comparative risk of real-world major and minor bleeding events over 12 months among patients prescribed different dual antiplatelet therapy (DAPT) and triple therapy (TT) regimens following PCI, CABG, or conservatively managed ACS?
Cohort
Yes
What is the comparative risk of real-world major and minor bleeding events over 12 months among patients prescribed different dual antiplatelet therapy (DAPT) and triple therapy (TT) regimens following PCI, CABG, or conservatively managed ACS?
Answers are grounded in this paper and cite their sources.
This study protocol outlines a target trial emulation framework using linked UK primary and secondary care databases to quantify the real-world incidence of both minor and major bleeding associated with DAPT and triple therapy after ACS, PCI, and CABG.
INTRODUCTION: 'Real world' bleeding in patients exposed to different regimens of dual antiplatelet therapy (DAPT) and triple therapy (TT, DAPT plus an anticoagulant) have a clinical and economic impact but have not been previously quantified. METHODS AND ANALYSIS: We will use linked Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) data to assemble populations eligible for three 'target trials' in patient groups: percutaneous coronary intervention (PCI); coronary artery bypass grafting (CABG); conservatively managed (medication only) acute coronary syndrome (ACS). Patients ≥18 years old will be eligible if, in CPRD records, they have: ≥1 year of data before the index event; no prescription for DAPT or anticoagulants in the preceding 3 months; a prescription for aspirin or DAPT within 2 months after discharge from the index event. The primary outcome will be any bleeding event (CPRD or HES) up to 12 months after the index event. We will estimate adjusted HR for time to first bleeding event comparing: aspirin and clopidogrel (reference) versus aspirin and prasugrel or aspirin and ticagrelor after PCI; and aspirin (reference) versus aspirin and clopidogrel after CABG and ACS. We will describe rates of bleeding in patients prescribed TT (DAPT plus an anticoagulant). Potential confounders will be identified systematically using literature review, semistructured interviews with clinicians and a short survey of clinicians. We will conduct sensitivity analyses addressing the robustness of results to the study's main limitation-that we will not be able to identify the intervention group for patients whose bleeding event occurs before a DAPT prescription in CPRD. ETHICS AND DISSEMINATION: This protocol was approved by the Independent Scientific Advisory Committee for the UK Medicines and Healthcare Products Regulatory Agency Database Research (protocol 16_126R) and the South West Cornwall and Plymouth Research Ethics Committee (17/SW/0092). The findings will be presented in peer-reviewed journals, lay summaries and briefing papers to commissioners/other stakeholders. TRIAL REGISTRATION NUMBER: 76607611; Pre-results.
No takes yet. Share an insight, caveat, or question.
Pufulete et al. (2019) conducted a cohort in Percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservatively managed acute coronary syndrome (ACS). Dual antiplatelet therapy (DAPT: aspirin plus clopidogrel, prasugrel, or ticagrelor) and triple therapy (TT: DAPT plus oral anticoagulant) vs. Aspirin plus clopidogrel (for PCI cohort); Aspirin monotherapy (for CABG and conservatively managed ACS cohorts) was evaluated on Any bleeding event (BARC type 2-5 recorded in CPRD or HES) up to 12 months after the index event. Dual antiplatelet and triple therapy regimens will be evaluated in three UK population-based cohorts emulating target trials to quantify 12-month real-world bleeding rates after PCI, CABG, or ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: